A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

作者：Banerji Udai^*; Dean Emma J.; Alejandro Perez-Fidalgo J.; Batist Gerald; Bedard Philippe L.; You Benoit; Westin Shannon N.; Kabos Peter; Garrett Michelle D.; Tall Mathew; Ambrose Helen; Barrett J. Carl; Carr T. Hedley; Cheung S. Y. Amy; Corcoran Claire; Cullberg Marie; Davies Barry R.; de Bruin Elza C.; Elvin Paul; Foxley Andrew; Lawrence Peter; Lindemann Justin P. O.; Maudsley Rhiannon; Pass Martin; Rowlands Vicky; Rugman Paul; Schiavon Gaia; Yates James

来源：Clinical Cancer Research, 2018, 24(9): 2050-2059.

DOI：10.1158/1078-0432.CCR-17-2260

Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety, tolerability, and pharmacokinetics of AZD5363, define a recommended dosing schedule, and evaluate preliminary clinical activity.
Experimental Design: Patients were aged >= 18 years with World Health Organization (WHO) performance status of 0 to 1. Dose escalation was conducted within separate continuous and intermittent [4 days/week (4/7) or 2 days/week (2/7)] schedules with safety, pharmacokinetic, and pharmacodynamic analyses. Expansion cohorts of approximately 20 patients each explored AZD5363 activity in PIK3CA-mutant breast and gynecologic cancers.
Results: MTDs were 320, 480, and 640 mg for continuous (n = 47), 4/7 (n = 21), and 2/7 (n = 22) schedules, respectively. Doselimiting toxicities were rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common adverse events were diarrhea (78%) and nausea (49%) and, for Common Terminology Criteria for Adverse Events grade 3 events, hyperglycemia (20%). The recommended phase II dose (480 mg bid, 4/7 intermittent) was assessed in PIK3CA-mutant breast and gynecologic expansion cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with RECIST responses of 4% and 8%. These responses were less than the prespecified 20% response rate; therefore, the criteria to stop further recruitment to the PIK3CA-mutant cohort were met.
Conclusions: At the recommended phase II dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors. Proof-of-concept responses were observed in patients with PIK3CA-mutant cancers treated with AZD5363.

• 出版日期2018-5-1
• 单位McGill